Analyst Ratings February 10, 2026

Goldman Lifts Roivant Sciences Target to $38, Cites 2026 Catalysts and Mosliciguat Opportunity

Bank keeps Buy rating as analysts weigh mid-cap growth potential amid mixed earnings and strong cash position

By Caleb Monroe ROIV
Goldman Lifts Roivant Sciences Target to $38, Cites 2026 Catalysts and Mosliciguat Opportunity
ROIV

Goldman Sachs increased its 12-month price target for Roivant Sciences to $38 from $36 and maintained a Buy rating, pointing to a string of 2026 clinical catalysts and a notable opportunity for mosliciguat in PH-ILD. Despite a recent earnings miss, the company’s cash-rich balance sheet and pipeline progress have driven significant stock gains and additional analyst target upgrades.

Key Points

  • Goldman Sachs raised its 12-month price target to $38 from $36 and kept a Buy rating for Roivant Sciences; shares trade at $27.67, near a 52-week high of $27.72.
  • Four of Roivant’s five remaining clinical catalysts are slated for 2026 and could together unlock more than approximately $10 billion in unadjusted peak sales; mosliciguat in PH-ILD is highlighted with a modeled $2.6 billion peak and 40% probability of success.
  • The company reported a larger-than-expected Q3 2026 loss and a significant revenue shortfall, yet the stock rose in pre-market trading—an outcome attributed to a strong cash position and pipeline developments.

Goldman Sachs has raised its 12-month price objective for Roivant Sciences (NASDAQ:ROIV) to $38.00 from $36.00 while keeping a Buy recommendation on the shares. The new target sits at the upper range of analyst expectations as the stock trades at $27.67, very close to its 52-week high of $27.72.

Roivant’s shares have posted strong recent performance, returning 25.94% over the last week and 156.44% over the prior 12 months. Goldman frames the company as entering the early phase of a multi-year sequence of clinical catalysts that could re-cast the company as a mid-cap biotech growth story.

Central to Goldman’s outlook is the concentration of remaining clinical milestones in 2026. The firm notes that four of Roivant’s five remaining clinical catalysts are set for 2026 and that, if realized, these events could collectively unlock more than approximately $10 billion in unadjusted peak sales.

Goldman singles out mosliciguat - the company’s program in pulmonary hypertension associated with interstitial lung disease (PH-ILD) - as a potentially underappreciated asset. The bank highlights a Phase 2 proof-of-concept readout expected in the second half of 2026 and models $2.6 billion in peak sales for mosliciguat, applying a 40% probability of success.

In its assessment of mosliciguat, Goldman cites the drug’s differentiated mechanism of action for the high-oxidative-stress environment characteristic of PH-ILD, supporting evidence from early hemodynamic data, and a once-daily dosing profile. The bank also points to a favorable tolerability profile that avoids the pronounced cough observed with Tyvaso, framing tolerability as a potential clinical advantage in a population with significant unmet needs.

Goldman’s scenario analysis outlines potential valuation movements: under bull and intermediate cases the firm sees 5%-13% upside to its current 12-month price target, which it translates into a 44%-55% upside relative to the present share price. Conversely, a bear case centered on clinical failure would trigger program discontinuation and an estimated 8% decline to the company’s overall valuation.

Financially, InvestingPro data cited by the bank indicates Roivant has a market capitalization of $19.8 billion. The same data set suggests analysts expect sales to decline in the current year. Roivant’s balance sheet is reported to carry more cash than debt, with liquid assets exceeding short-term obligations, offering a degree of financial flexibility. At the same time, the company is not profitable, registering a diluted EPS of -$1.17 over the last twelve months.

Outside the valuation and pipeline discussion, Roivant recently reported Q3 2026 results that included a larger-than-expected loss and a material revenue shortfall. Despite those headline figures, the company’s stock experienced a notable pre-market uptick, market observers attribute the move to Roivant’s cash position and continued progress across its drug programs.

Brokerage coverage has shown parallel adjustments to sentiment: Citi raised its price target on Roivant to $35 from $26 and maintained a Buy rating - a 35% upward revision from its prior valuation.

Taken together, these developments underline a mixed profile for Roivant: uneven near-term financial results alongside optimistic forecasts tied to upcoming clinical readouts and a cash cushion that supports ongoing development activity.


Additional context and where to find more

InvestingPro is cited as the source for market-cap and balance-sheet snapshot details and notes that a comprehensive Pro Research Report on Roivant is available within its coverage universe of more than 1,400 US equities.

Risks

  • Clinical trial failure - a failed program would likely be discontinued and could reduce Roivant’s overall valuation by an estimated 8%, affecting biotech investors and equity markets tied to clinical-stage drug developers.
  • Near-term financial weakness - analysts expect sales to decline this year and the company reported a larger-than-expected quarterly loss and revenue shortfall, which impacts investor sentiment in the healthcare and biotech sectors.
  • Binary catalyst timing - with four of five remaining clinical catalysts concentrated in 2026, the company’s market valuation is sensitive to the timing and outcomes of those readouts, creating volatility for investors focused on biotech and life sciences stocks.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026